FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3157253243> ?p ?o ?g. }

• W3157253243 endingPage "416" @default.
• W3157253243 startingPage "405" @default.
• W3157253243 abstract "Purpose Neoadjuvant concurrent chemoradiation therapy (nCRT) plus surgery has been a standard treatment for locoregionally advanced esophageal cancer and carcinoma of the gastroesophageal junction (EC/GEJ), but the optimal preoperative radiation dose is still unclear. We performed this systematic review to explore the treatment efficacy and toxicity of different radiation dose levels and find an optimal dose‐fractionation strategy in EC/GEJ patients receiving nCRT. Methods and Materials Embase and Ovid Medline were searched for articles involving cases of operable squamous and adenocarcinoma of the esophagus and GEJ in which patients received nCRT up to a dose of 50.4 Gy in 28 fractions that were published until July 2019, when the search was performed. Physical dose distributions were converted to biologically equivalent doses (BEDs), which were described in units of gray (alpha/beta). Pooled rates of overall survival (OS), progression-free survival (PFS), failure patterns, and toxicities were compared between lower-dose radiation therapy (LDRT; BED ≤48.85 Gy10) and higher-dose radiation therapy (HDRT; BED >48.85 Gy10) for patients treated with nCRT. Results A total of 110 studies with 7577 EC/GEJ patients receiving nCRT were included in this pooled analysis. Both the PFS and OS rates of patients receiving LDRT were significantly higher than those of patients receiving HDRT. Patients receiving LDRT had improved safety regarding treatment-related adverse events and lower distant failure rates than patients receiving HDRT. Utilization of modern radiation therapy (RT) techniques, including 3-dimensional conformal RT and intensity modulated RT, was associated with improved oncologic outcomes compared with 2-dimensional methods. Subgroup analysis showed that EC/GEJ patients receiving conventionally fractionated radiation to a dose of 40.0 to 41.4 Gy in 20-23 fractions showed improved OS compared with those receiving radiation above this dose. Conclusions Based on the limited data, nCRT using BED ≤48.85 Gy10 was suitable for locoregionally advanced, resectable EC/GEJ. A total dose of 40.0 to 41.4 Gy in 20 to 23 fractions using modern RT techniques might provide the optimal therapeutic ratio. Neoadjuvant concurrent chemoradiation therapy (nCRT) plus surgery has been a standard treatment for locoregionally advanced esophageal cancer and carcinoma of the gastroesophageal junction (EC/GEJ), but the optimal preoperative radiation dose is still unclear. We performed this systematic review to explore the treatment efficacy and toxicity of different radiation dose levels and find an optimal dose‐fractionation strategy in EC/GEJ patients receiving nCRT. Embase and Ovid Medline were searched for articles involving cases of operable squamous and adenocarcinoma of the esophagus and GEJ in which patients received nCRT up to a dose of 50.4 Gy in 28 fractions that were published until July 2019, when the search was performed. Physical dose distributions were converted to biologically equivalent doses (BEDs), which were described in units of gray (alpha/beta). Pooled rates of overall survival (OS), progression-free survival (PFS), failure patterns, and toxicities were compared between lower-dose radiation therapy (LDRT; BED ≤48.85 Gy10) and higher-dose radiation therapy (HDRT; BED >48.85 Gy10) for patients treated with nCRT. A total of 110 studies with 7577 EC/GEJ patients receiving nCRT were included in this pooled analysis. Both the PFS and OS rates of patients receiving LDRT were significantly higher than those of patients receiving HDRT. Patients receiving LDRT had improved safety regarding treatment-related adverse events and lower distant failure rates than patients receiving HDRT. Utilization of modern radiation therapy (RT) techniques, including 3-dimensional conformal RT and intensity modulated RT, was associated with improved oncologic outcomes compared with 2-dimensional methods. Subgroup analysis showed that EC/GEJ patients receiving conventionally fractionated radiation to a dose of 40.0 to 41.4 Gy in 20-23 fractions showed improved OS compared with those receiving radiation above this dose. Based on the limited data, nCRT using BED ≤48.85 Gy10 was suitable for locoregionally advanced, resectable EC/GEJ. A total dose of 40.0 to 41.4 Gy in 20 to 23 fractions using modern RT techniques might provide the optimal therapeutic ratio." @default.
• W3157253243 created "2021-05-10" @default.
• W3157253243 creator A5005415696 @default.
• W3157253243 creator A5011375904 @default.
• W3157253243 creator A5012493900 @default.
• W3157253243 creator A5024965407 @default.
• W3157253243 creator A5048473316 @default.
• W3157253243 creator A5049547809 @default.
• W3157253243 creator A5051897438 @default.
• W3157253243 creator A5052955198 @default.
• W3157253243 creator A5057348374 @default.
• W3157253243 creator A5058178201 @default.
• W3157253243 creator A5060002817 @default.
• W3157253243 creator A5063965044 @default.
• W3157253243 creator A5066573725 @default.
• W3157253243 creator A5090008098 @default.
• W3157253243 creator A5091529832 @default.
• W3157253243 date "2021-10-01" @default.
• W3157253243 modified "2023-09-24" @default.
• W3157253243 title "Comparison of Clinical Efficacy of Neoadjuvant Chemoradiation Therapy Between Lower and Higher Radiation Doses for Carcinoma of the Esophagus and Gastroesophageal Junction: A Systematic Review" @default.
• W3157253243 cites W1503013336 @default.
• W3157253243 cites W1922694287 @default.
• W3157253243 cites W1971737397 @default.
• W3157253243 cites W1984242303 @default.
• W3157253243 cites W2098923148 @default.
• W3157253243 cites W2099918668 @default.
• W3157253243 cites W2112455219 @default.
• W3157253243 cites W2116475791 @default.
• W3157253243 cites W2120603938 @default.
• W3157253243 cites W2125118126 @default.
• W3157253243 cites W2127996441 @default.
• W3157253243 cites W2129292725 @default.
• W3157253243 cites W2169205464 @default.
• W3157253243 cites W2593400240 @default.
• W3157253243 cites W2600730117 @default.
• W3157253243 cites W2609606527 @default.
• W3157253243 cites W2725572687 @default.
• W3157253243 cites W2765470263 @default.
• W3157253243 cites W2810304435 @default.
• W3157253243 cites W2885107163 @default.
• W3157253243 cites W2898999211 @default.
• W3157253243 cites W2914557607 @default.
• W3157253243 cites W2917146047 @default.
• W3157253243 cites W2922650405 @default.
• W3157253243 cites W2999417355 @default.
• W3157253243 cites W3012051758 @default.
• W3157253243 cites W3080471106 @default.
• W3157253243 cites W3128646645 @default.
• W3157253243 cites W4211125721 @default.
• W3157253243 doi "https://doi.org/10.1016/j.ijrobp.2021.04.031" @default.
• W3157253243 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33964352" @default.
• W3157253243 hasPublicationYear "2021" @default.
• W3157253243 type Work @default.
• W3157253243 sameAs 3157253243 @default.
• W3157253243 citedByCount "16" @default.
• W3157253243 countsByYear W31572532432021 @default.
• W3157253243 countsByYear W31572532432022 @default.
• W3157253243 countsByYear W31572532432023 @default.
• W3157253243 crossrefType "journal-article" @default.
• W3157253243 hasAuthorship W3157253243A5005415696 @default.
• W3157253243 hasAuthorship W3157253243A5011375904 @default.
• W3157253243 hasAuthorship W3157253243A5012493900 @default.
• W3157253243 hasAuthorship W3157253243A5024965407 @default.
• W3157253243 hasAuthorship W3157253243A5048473316 @default.
• W3157253243 hasAuthorship W3157253243A5049547809 @default.
• W3157253243 hasAuthorship W3157253243A5051897438 @default.
• W3157253243 hasAuthorship W3157253243A5052955198 @default.
• W3157253243 hasAuthorship W3157253243A5057348374 @default.
• W3157253243 hasAuthorship W3157253243A5058178201 @default.
• W3157253243 hasAuthorship W3157253243A5060002817 @default.
• W3157253243 hasAuthorship W3157253243A5063965044 @default.
• W3157253243 hasAuthorship W3157253243A5066573725 @default.
• W3157253243 hasAuthorship W3157253243A5090008098 @default.
• W3157253243 hasAuthorship W3157253243A5091529832 @default.
• W3157253243 hasConcept C121608353 @default.
• W3157253243 hasConcept C126322002 @default.
• W3157253243 hasConcept C126894567 @default.
• W3157253243 hasConcept C143998085 @default.
• W3157253243 hasConcept C155806632 @default.
• W3157253243 hasConcept C197934379 @default.
• W3157253243 hasConcept C2777546739 @default.
• W3157253243 hasConcept C2777819096 @default.
• W3157253243 hasConcept C2778292576 @default.
• W3157253243 hasConcept C2779742542 @default.
• W3157253243 hasConcept C2781182431 @default.
• W3157253243 hasConcept C509974204 @default.
• W3157253243 hasConcept C530470458 @default.
• W3157253243 hasConcept C71924100 @default.
• W3157253243 hasConceptScore W3157253243C121608353 @default.
• W3157253243 hasConceptScore W3157253243C126322002 @default.
• W3157253243 hasConceptScore W3157253243C126894567 @default.
• W3157253243 hasConceptScore W3157253243C143998085 @default.
• W3157253243 hasConceptScore W3157253243C155806632 @default.
• W3157253243 hasConceptScore W3157253243C197934379 @default.
• W3157253243 hasConceptScore W3157253243C2777546739 @default.
• W3157253243 hasConceptScore W3157253243C2777819096 @default.
• W3157253243 hasConceptScore W3157253243C2778292576 @default.
• W3157253243 hasConceptScore W3157253243C2779742542 @default.

• next